This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
by Ahan Chakraborty
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers
by Zacks Equity Research
Bayer and Kumquat launch a phase I study of KQB548, aiming to target various KRAS G12D-mutated tumors like pancreatic, colorectal and lung cancer.
JNJPositive Net Change BAYRYPositive Net Change ANIPNegative Net Change EXASPositive Net Change
pharmaceuticals
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?
by Kinjel Shah
Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.
LLYPositive Net Change ABBVNegative Net Change
pharmaceuticals
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
by Ekta Bagri
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
AZNNegative Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights SAP, Novartis, Philip Morris International, ImmuCell and ClearOne
by Zacks Equity Research
SAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.
NVSNegative Net Change PMPositive Net Change SAPNegative Net Change CLROPositive Net Change ICCCPositive Net Change
communications computers consumer-staples medical pharmaceuticals
Top Stock Reports for SAP, Novartis & Philip Morris
by Mark Vickery
SAP, Novartis and Philip Morris headline today's top Zacks reports, each showing strong momentum and strategic growth drivers despite industry headwinds.
NVSNegative Net Change PMPositive Net Change SAPNegative Net Change CLROPositive Net Change ICCCPositive Net Change UBERNegative Net Change NETPositive Net Change HOODPositive Net Change
communications computers consumer-staples medical pharmaceuticals
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
by Zacks Equity Research
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
JNJPositive Net Change BAYRYPositive Net Change FOLDPositive Net Change SPROPositive Net Change
biotechnology biotechs medical pharmaceuticals
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
by Zacks Equity Research
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
KALANegative Net Change ALLOPositive Net Change AKROPositive Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
by Zacks Equity Research
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
BIIBNegative Net Change BMYPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
by Kinjel Shah
Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.
AZNNegative Net Change BMYPositive Net Change PFENegative Net Change MRKPositive Net Change
pharmaceuticals
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
by Kinjel Shah
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
NVSNegative Net Change JNJPositive Net Change PFENegative Net Change MRKPositive Net Change BAYRYPositive Net Change
pharmaceuticals
Amgen Unveils New DTC Program, Cuts Cholesterol Drug Price by 60%
by Zacks Equity Research
AMGN rolls out AmgenNow, a direct-to-consumer program debuting with Repatha at a 60% lower price to boost patient access and affordability.
PFENegative Net Change AMGNPositive Net Change GDRXPositive Net Change
biotechs medical pharmaceuticals
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
by Zacks Equity Research
Merck broadens its tulisokibart clinical program with three new phase IIb studies, deepening its reach across immune-mediated inflammatory diseases.
MRKPositive Net Change ALLOPositive Net Change AKROPositive Net Change CMMBNegative Net Change
pharmaceuticals
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
by Zacks Equity Research
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
NVONegative Net Change FOLDPositive Net Change AVDLNegative Net Change SKYENo Net Change
biotechnology biotechs medical pharmaceuticals
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
by Ahan Chakraborty
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
by Zacks Equity Research
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Johnson & Johnson and Willis Lease Finance
by Zacks Equity Research
Zacks Analyst Blog highlights Microsoft, Amazon, Johnson & Johnson, and Willis Lease Finance as analysts weigh AI growth, pharma resilience, and niche leasing strength.
AMZNPositive Net Change MSFTNegative Net Change JNJPositive Net Change WLFCNegative Net Change
computers pharmaceuticals retail transportation
The Zacks Analyst Blog Highlights Delta Airlines, Levi Strauss, Pfizer, Zoom Communications , Fresnillo and Kyocera
by Zacks Equity Research
Zacks Analyst Blog features Delta Airlines, Levi Strauss, Pfizer, Zoom Communications, Fresnillo, and Kyocera as markets hit record highs despite a U.S. government shutdown.
PFENegative Net Change DALPositive Net Change FNLPFPositive Net Change KYOCYPositive Net Change LEVINegative Net Change ZMPositive Net Change
computers pharmaceuticals precious-metals retail transportation
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
PFENegative Net Change MRKPositive Net Change SMMTNegative Net Change VRNANo Net Change
pharmaceuticals
Top Analyst Reports for Microsoft, Amazon.com & Johnson & Johnson
by Mark Vickery
Microsoft rides AI and cloud growth, Amazon leans on AWS and Prime, and Johnson & Johnson gains from strong pharma momentum despite patent risks.
AMZNPositive Net Change GDNegative Net Change MSFTNegative Net Change JNJPositive Net Change AEMNegative Net Change KMINegative Net Change WLFCNegative Net Change
computers pharmaceuticals retail transportation
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
by Zacks Equity Research
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
AZNNegative Net Change PFENegative Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer
by Zacks Equity Research
Roche gains FDA approval for Tecentriqs expanded label, marking the first combo maintenance therapy for extensive-stage small cell lung cancer.
RHHBYPositive Net Change JAZZPositive Net Change ETNBPositive Net Change
biotechnology biotechs medical pharmaceuticals
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
by Sundeep Ganoria
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
AZNNegative Net Change PFENegative Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal
by Zacks Equity Research
Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.
CRMDNegative Net Change MRUSPositive Net Change KNSANegative Net Change GMABNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk
by Zacks Equity Research
Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.
PFENegative Net Change NVONegative Net Change MRKPositive Net Change LLYPositive Net Change ABBVNegative Net Change
medical pharmaceuticals